Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.
“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”
Journal of Urology 2014 Nov 15 epub. PMID:25463993
Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993
Among men from the US FDA registration trial, we found that the Prostate Health Index was a better predictor of clinically significant prostate cancer compared to any of its component parts (total, free or -2proPSA). At the 90% sensitivity cut point for phi (a score less than 28.6), 30% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free PSA.